Silas Inman

Truqap Extends Radiographic Progression-Free Survival in Some With Prostate Cancer

Giredestrant/Afinitor Reduces Progression in Advanced Breast Cancer

The antibody-drug conjugate zilovertamab vedotin plus Rituxan and chemotherapy showed an objective response rate of 56.3% in relapsed/refractory DLBCL.

Akeega delayed cancer growth and symptoms in patients with castration-sensitive prostate cancer and HRR gene mutations.

Belamaf plus bortezomib and dexamethasone lengthened the time patients with relapsed or refractory myeloma lived before their disease got worse.

Opdivo plus Yervoy in the neoadjuvant setting reduced the risk for recurrence, progression or death, potentially offering patients with stage 3 melanoma a new standard of care.

The recent phase 3 TRANSFORM-1 study concluded that navitoclax combined with Jakafi showed significant spleen volume reductions in patients with myelofibrosis.

Patients with grade 2 IDH-mutant glioma (a type of brain cancer) experienced a 61% reduced risk of progression or desk when treated with vorasidenib (AG-881) compared with placebo, according to results from the phase 3 INDIGO clinical trial, presented at the 2023 ASCO Annual Meeting and published in the New England Journal of Medicine. Progression-free survival (time from treatment until disease progression) with vorasidenib was 27.7 months compared with 11.1 months for those treated with pla…

Adding Keytruda (pembrolizumab) to pre-surgical chemotherapy and then again after surgery led to improvements in outcomes for patients with early-stage non-small cell lung cancer (NSCLC), according to findings from the phase 3 KEYNOTE-671 study presented at the 2023 ASCO Annual Meeting and simultaneously published in the New England Journal of Medicine. In particular, this Keytruda regimen improved event-free survival, which is the time a patient lives without complications from the disease,…

Progression-free survival and overall response rates greatly improved in patients with CLL/SLL treated with Brukinsa compared with Imbruvica.